A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma

Richard S. Surwit; Robert S. Gilgor; Lyle M. Allen; Madeleine Duvic

doi:10.1001/archderm.1984.01650390051010

A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma

Richard S. Surwit, Robert S. Gilgor, Lyle M. Allen, Madeleine Duvic

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.

Original language	English (US)
Pages (from-to)	329-331
Number of pages	3
Journal	Archives of Dermatology
Volume	120
Issue number	3
DOIs	https://doi.org/10.1001/archderm.1984.01650390051010
State	Published - Mar 1984
Externally published	Yes

ASJC Scopus subject areas

Dermatology

Access to Document

10.1001/archderm.1984.01650390051010

Cite this

@article{a8e03c5c8a5d4f9ab25e2f71b4503eb0,

title = "A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma",

abstract = "Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.",

author = "Surwit, {Richard S.} and Gilgor, {Robert S.} and Allen, {Lyle M.} and Madeleine Duvic",

year = "1984",

month = mar,

doi = "10.1001/archderm.1984.01650390051010",

language = "English (US)",

volume = "120",

pages = "329--331",

journal = "Archives of Dermatology",

issn = "0003-987X",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma

AU - Surwit, Richard S.

AU - Gilgor, Robert S.

AU - Allen, Lyle M.

AU - Duvic, Madeleine

PY - 1984/3

Y1 - 1984/3

N2 - Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.

AB - Nineteen patients with Raynaud's phenomenon in conjunction with progressive systemic sclerosis were given either prazosin hydrochloride (1 mg orally three times a day) or a placebo for eight weeks, after which the treatment procedure was reversed for four weeks. Prazosin was shown to be effective in reducing both the frequency and the severity of vasospasm reported by the patients.

UR - http://www.scopus.com/inward/record.url?scp=0021332604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021332604&partnerID=8YFLogxK

U2 - 10.1001/archderm.1984.01650390051010

DO - 10.1001/archderm.1984.01650390051010

M3 - Article

C2 - 6367665

AN - SCOPUS:0021332604

SN - 0003-987X

VL - 120

SP - 329

EP - 331

JO - Archives of Dermatology

JF - Archives of Dermatology

IS - 3

ER -

A Double-blind Study of Prazosin in the Treatment of Raynaud's Phenomenon in Scleroderma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this